Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial

Lancet Diabetes and Endocrinology,The - Tập 3 - Trang 123-131 - 2015
Anna Axelsson1,2, Kasper Iversen3, Niels Vejlstrup1, Carolyn Ho4, Jakob Norsk1, Lasse Langhoff1, Kiril Ahtarovski1, Pernille Corell5, Ole Havndrup5, Morten Jensen1, Henning Bundgaard1
1Unit for Inherited Cardiac Diseases, Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2Seidman Laboratory, Department of Genetics, Harvard Medical School, Boston, MA, USA
3Department of Cardiology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
4Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA
5Department of Cardiology, Roskilde Hospital, Roskilde, Denmark

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Lancet Diabetes and Endocrinology,The

Tập 3

123-131

Thông tin tác giả